Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1727196 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $49.06Day −0.63%Mkt cap $5.9B1Y +31.6%Off 52W high −16.1%Vol (1Y) 62.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,052 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest14.7% of sh out |
| Days to cover16.1d |
| 13F net flow (QoQ)+9.76% |
| Top-10 13F concentration57.2% |
| Next report (est.)2026-08-08 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$408.7M |
| ROE−123.1% |
| Debt / equity0.41× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+11.4% |
| 1Y+31.6% |
| 3Y+591.0% |
| 5Y+51.3% |
| Since incept. (ann.)+15.1% |
Total return through 2026-07-29 · series begins 2018-05-24. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)62.3% |
| Ann. volatility (3Y)221.4% |
| Sharpe (1Y)0.76 |
| Sharpe (3Y)0.72 |
| Max drawdown (1Y)−31.9% |
| Max drawdown (3Y)−65.2% |
| Beta (3Y vs SPY)−1.04 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 17.2M | $848M | 14.39% | +12.1% |
| Siren, L.L.C. | 10.8M | $532M | 9.03% | +0.0% |
| Redmile Group, LLC | 9.1M | $446M | 7.57% | +73.7% |
| BlackRock, Inc. | 7.5M | $367M | 6.23% | +3.5% |
| SAMSARA BIOCAPITAL, LLC | 6.9M | $339M | 5.76% | +0.0% |
| WELLINGTON MANAGEMENT GROUP LLP | 6.7M | $330M | 5.61% | +16.6% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.2M | $305M | 5.18% | −3.1% |
| Orbis Allan Gray Ltd | 4.2M | $205M | 3.49% | +21.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 111.7% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 14,906,364 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.83 | — | $0 | — |
| 2025-09-30 | 2025-11-14 | −$0.90 | — | — | — |
| 2025-06-30 | 2025-08-06 | −$0.98 | — | — | — |
| 2025-03-31 | 2025-05-14 | −$0.67 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-08 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
